’Explosive’ growth in foreign drug testing raises ethical questions
Peek inside any American family's medicine cabinet and you're likely to find a drug that was tested in a foreign country. Pharmaceutical companies have been shifting research overseas for years and the number of foreign trials has skyrocketed. The Department of Health and Human Services reports more than a 2,000% increase in the number of foreign trials for U.S. drugs over the past two decades. In 2008, about 80% of drug applications approved by the Food and Drug Administration contained data from foreign clinical trials. The growth in developing countries and emerging economies in particular has been "explosive" said Arthur Caplan, MD, director of the Center for Bioethics at University of Pennsylvania's Perelman School of Medicine. Caplan explained the appeal of holding clinical trials in developing countries and the ethical issues raised by this research trend.
- Interventional Radiology No Longer a Sub-Specialty
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Acute Kidney Injury Gets New Focus
- Transforming Cancer Care
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Evidence-Based Practice and Nursing Research: Avoiding Confusion
- mHealth Tackles Readmissions
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Sharp HealthCare Leaves Pioneer ACO Program
- Proton Beam Therapy Poised for Growth in US